Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma and the SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids in adult patients with evaporative dry eye disease due to meibomian gland disfunction.
企業コードSGHT
会社名Sight Sciences Inc
上場日Jul 15, 2021
最高経営責任者「CEO」Mr. Paul Badawi
従業員数216
証券種類Ordinary Share
決算期末Jul 15
本社所在地4040 Campbell Ave,
都市MENLO PARK
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号94025
電話番号14158890550
ウェブサイトhttps://www.sightsciences.com/
企業コードSGHT
上場日Jul 15, 2021
最高経営責任者「CEO」Mr. Paul Badawi
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし